Overview Milestone payments are contingent fees in pharmaceutical and biotech deals that become due when a product achieves specific goals. They are ubiquitous in licensing and collaboration agreements (and even in M&A via so-called earn-outs or CVRs) because they help bridge valuation gaps between partners. Rather

Introduction and Company Overview Revolution Medicines (NASDAQ: RVMD) is a late-stage oncology biotech focused on targeting the RAS oncogene family, historically considered "undruggable." The company has developed a pipeline of RAS(ON) inhibitors – small molecules that bind RAS in its active, GTP-bound state – designed to suppress

Executive Summary Breakout Ventures is a San Francisco-based venture capital firm specializing in life sciences and "deep tech" investments. Spun out of a philanthropic seed program in 2016, Breakout Ventures has quickly carved a niche funding early-stage companies where biology, chemistry and technology converge. This report

Current Market Dynamics and Transaction Volume The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse in March 2023. Prior to its failure, SVB serviced approximately 50% of early-stage U.S. biotechnology companies, representing a concentration risk that materialized catastrophically. The subsequent market restructuring resulted

The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of 2020–2021, leaving many biotech companies cash-hungry in what observers dub a "biotech winter." In this environment, Private Investments in Public Equity (PIPEs) have emerged as a

1. Historical Examples of Disease-Linked Bonds Pandemic Bonds (World Bank PEF) The most prominent example is the World Bank's Pandemic Emergency Financing Facility (PEF) bonds, launched in June 2017 in response to the devastating 2014–16 West African Ebola outbreak. This was the first time pandemic risk

The week of September 15-20, 2025 witnessed over 40 distinct biotech pharmaceutical transactions totaling more than $6 billion in disclosed value, with potential milestone values exceeding $14 billion. This period marked a critical inflection point in cross-border licensing activity, with Chinese biotechs securing major Western partnerships despite looming

In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision support, and diagnostics proudly tout proprietary artificial intelligence as their secret sauce. Yet peel back the glossy pitch decks, and many of these supposed AI pioneers are simply piggybacking

Poxel SA, a French biopharmaceutical company that successfully developed and commercialized the first-in-class diabetes drug TWYMEEG® in Japan, filed for judicial reorganization on July 29, 2025, after shareholders rejected critical financial resolutions triggering immediate debt defaults despite securing a $50 million royalty monetization deal with OrbiMed just months

Executive Summary OrbiMed's Royalty & Credit Opportunities strategy has emerged as a prominent non-dilutive financing platform in the healthcare sector. Since launching its first dedicated royalty/credit fund in 2011, OrbiMed has steadily expanded this business, raising successive funds and deploying capital into royalty monetizations and credit